ERAS
Erasca, Inc. [ERAS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ERAS Stock Summary
Top ERAS Correlated Resources
ERAS
Top 10 Correlated ETFs
ERAS
Top 10 Correlated Stocks
ERAS
In the News
ERAS Financial details
Company Rating
-
Market Cap
319.65M
Income
-121.22M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
126
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-1.42
Forward P/E
-
PEG
0.24
P/S
-
P/B
-0.55
P/C
-
P/FCF
-2.54
Quick Ratio
11.1
Current Ratio
11.45
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.81
EPS next Y
-
EPS next Q
-
EPS this Y
-57.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-20.95%
SMA50
-34.64%
SMA100
-57.45%
Inst Own
-
Inst Trans
-
ROA
-53%
ROE
74%
ROC
-0.12%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.51-3.375
52W High
-58.67%
52W Low
+24%
RSI
46.41
Rel Volume
2.09
Avg Volume
813.68K
Volume
1.7M
Perf Week
3.33%
Perf Month
-18.95%
Perf Quarter
-51.94%
Perf Half Y
-54.58%
-
-
-
-
Beta
1.104
-
-
Volatility
0.06%, 0.15%
Prev Close
6.9%
Price
1.24
Change
6.9%
Company Profile
- Volume Average 813.68K
- Market Capitalization 319.65M
- Employee 126
- CEO Dr. Jonathan E. Lim M.D.
- Headquarters San Diego,CA,US
- IPO Date 2021-07-16
-
Website
https://www.erasca.com 
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
